Compare HubSpot Inc (HUBS) vs Illumina, Inc. (ILMN) Price & Performance

HubSpot IncTrade

Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

HubSpot Inc vs Illumina, Inc. — how do they compare? HubSpot Inc trades at $217.26 (market cap $11.84B), while Illumina, Inc. trades at $192.7 (market cap $27.94B). The key difference: Illumina, Inc. is far larger — about 2.4× HubSpot Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.

	HUBS	ILMN
Market Cap	$11.84B	$27.94B
Sector	Technology	Health
52-Week High	$560.90	$194.33
52-Week Low	$170.39	$91.00
Enterprise Value	$10.39B	$29.33B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

HUBS

View details →

ILMN

ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.24/7 Wall Street · 12 hours agoNeutral Cancer biomarkers market to hit $54.48B by 2032, driven by tech advances and Asia-Pacific growthResearchandmarkets.Com · 4 days agoBullish New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral View details →

About HubSpot Inc

HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.